KCNQ1 potassium channel activator

This page covers all KCNQ1 potassium channel activator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting KCNQ1.

Targets

KCNQ1

Phase 3 pipeline (1)

• Etavopivat Tablets Low dose · Forma Therapeutics, Inc. · Hematology/Oncology
  Etavopivat activates the KCNQ1 potassium channel to increase fetal hemoglobin (HbF) production in red blood cells.